学术周报 · IF≥10

消化内科领域文献阅读汇编

2026年第44周 (2026-10-31) | PubMed (NLM) · DeepSeek 中英双语
数据来源: PubMed E-utilities · 影响因子筛选≥10 · 完整摘要不截断
收录论文
19
临床研究
8
基础研究
11
IF≥20
8
IF 10-20
11
子领域
12
期刊种类
18
数据日期
2026-10-31

★本周 Top 10 高影响力文献

#论文期刊IF
1Genetic variants shape single-cell chromatin accessibility and disease risk.NatureIF 56.1
2Intestinal Candida albicans promotes HCC progression and anti-PD-1 resistance via IL-17A and Trem2+ ...Journal of hepatologyIF 40.1
3A microbiome-reactive TMIGD2hi Th17 subset is spatially enriched at the intestinal epithelium and ex...ImmunityIF 30.6
4TASTY AND HEALTHY DIET REDUCES FECAL CALPROTECTIN IN HIGH-RISK FIRST-DEGREE RELATIVES OF PATIENTS WI...GastroenterologyIF 29.7
5Bioinspired soft enteroscopic robot for intestinal locomotion, steering, and intervention.Science roboticsIF 25.5
6Microbial products trigger chemosensory dialogues through intestinal G protein-coupled receptors.Cell host & microbeIF 23.2
7GLP-1 receptor agonists and adverse outcomes in patients with type 2 diabetes and chronic viral hepa...Clinical and molecular hepatologyIF 21.7
8Hepatitis E virus infections in immunocompromised patients.Clinical microbiology reviewsIF 20.7
9Development and multicenter validation of a cfDNA methylation-based PCR assay (myESCAP) with machine...Journal of advanced researchIF 17.1
10Potassium-Competitive Acid Blockers in GERD and Helicobacter pylori Infection: The Emerging Role of ...DrugsIF 14.7

Ŧ期刊分布统计

期刊篇数IF
Critical reviews in food science and nutrition2IF 10.6
Clinical reviews in allergy & immunology1IF 11.5
Journal of advanced research1IF 17.1
EBioMedicine1IF 11.2
Food chemistry1IF 10.4
Trends in immunology1IF 13.1
Cell host & microbe1IF 23.2
ACS sensors1IF 10.9
Nature1IF 56.1
Science robotics1IF 25.5

1炎症性肠病/IBD (5篇)

临床研究 (1篇)

Gastroenterology IF 29.7 2026-10-26 PMID: 42933673
With the rising prevalence of inflammatory bowel disease (IBD), preventing new-onset disease becomes a priority. The PIONIR (Preventing IBD ONset in Individuals at Risk) randomized controlled trial explored whether the Tasty&Healthy (T&H) diet reduces inflammatory markers in high-risk first-degree relatives (FDRs) of patients with Crohn's disease (CD). FDRs with persistently elevated fecal calprotectin (FC, >70μg/g) and, at most, nonspecific mucosal abnormalities (edema or ≤10 aphthous ulcers) on video-capsule endoscopy or ileocolonoscopy were randomized to T&H or habitual diet (HD) for 8 weeks, followed by crossover for additional 8 weeks. Treatment effect on the primary outcome, FC response, was analyzed using generalized estimating equations for the two-period, two-sequence crossover design, following the intention-to-treat principle. Twenty-nine FDRs were randomized (n=14 T&H-first, n=15 HD-first). At week 8, median FC was lower with T&H (64μg/g [IQR 44-127]) vs. HD (112μg/g [74-227]; P=.022). FC decreased by ≥50% in 71% on T&H versus 27% on HD (RR=2.68 [95%CI 1.09-6.60]; P=.016). Across both crossover periods, estimated marginal mean FC declined from 185μg/g [95%CI 144-237] by 61% to 72μg/g [95%CI 57-91] with T&H, versus 38% to 114μg/g [95%CI 93-140] with HD (ratio 0.63 [95%CI 0.51-0.80], translating to 37% overall decrease with T&H; P<0.001). Six microbial species differed between diets after FDR correction. By week 8, 79% rated T&H acceptable and 83% had good or complete adherence. These findings demonstrate the modifiability of low-grade intestinal inflammation in healthy high-risk FDRs with persistent FC elevation but without diagnostic endoscopic evidence of CD, supporting long-term dietary prevention trials (ClinicalTrials.gov #NCT05211518).
中文摘要:随着炎症性肠病(IBD)患病率上升,预防新发疾病成为优先事项。PIONIR(Preventing IBD ONset in Individuals at Risk)随机对照试验探讨美味健康(T&H)饮食能否降低克罗恩病(CD)患者高危一级亲属(FDRs)的炎症标志物。持续粪便钙卫蛋白(FC)升高(>70μg/g)且在视频胶囊内镜或回结肠镜检查中最多仅有非特异性黏膜异常(水肿或≤10个阿弗他溃疡)的FDRs被随机分配接受T&H饮食或习惯饮食(HD)8周,随后交叉再接受8周。主要结局为FC应答,按意向性治疗原则,采用适用于两阶段两序列交叉设计的广义估计方程分析饮食的治疗效应。共随机29名FDRs(T&H先14名,HD先15名)。第8周时,T&H组FC中位数低于HD组(64μg/g [IQR 44-127] 对 112μg/g [74-227];P=.022)。T&H组71%的受试者FC下降≥50%,HD组为27%(RR=2.68 [95%CI 1.09-6.60];P=.016)。在两个交叉阶段合并分析中,T&H组估计边际平均FC从185μg/g [95%CI 144-237]下降61%至72μg/g [95%CI 57-91],HD组下降38%至114μg/g [95%CI 93-140](比值0.63 [95%CI 0.51-0.80],相当于T&H总体下降37%;P<0.001)。经FDR校正后,有6种微生物物种在两种饮食间存在差异。至第8周,79%的受试者认为T&H可接受,83%依从性良好或完全依从。这些发现表明,在无CD诊断性内镜证据但FC持续升高的健康高危FDRs中,低度肠道炎症具有可改变性,支持开展长期饮食预防试验(ClinicalTrials.gov #NCT05211518)。

基础研究 (4篇)

Trends in immunology IF 13.1 2026-10-29 PMID: 42957455
Epithelial cell death in inflammatory bowel disease has been considered a consequence of inflammation. Pang et al. demonstrate that inflammation reshapes epithelial populations into death-prone states, with receptor-interacting serine/threonine-protein kinase 3-associated necroptotic signaling followed by cell-type-specific mitochondrial apoptosis. Persistent death signaling that extends beyond inflammatory control predicts relapse and reveals a path to molecular healing.
中文摘要:炎症性肠病中的上皮细胞死亡一直被视为炎症的结果。Pang等证明,炎症使上皮细胞群体重塑为易死亡状态,涉及受体相互作用丝氨酸/苏氨酸蛋白激酶3相关的坏死性凋亡信号,随后发生细胞类型特异性的线粒体凋亡。超出炎症控制而持续存在的死亡信号可预测复发,并揭示通往分子愈合的路径。
Cell host & microbe IF 23.2 2026-10-29 PMID: 42956747
Organismal reactions to changing environmental conditions require information relays that sense cues and elicit appropriate responses. G protein-coupled receptors (GPCRs), including olfactory receptors, comprise the largest receptor family that recognizes environmental cues, consisting of over 800 genes in the human genome. Here, by screening libraries of gut metabolites and natural products using a multiplexed GPCR reporter system, GPCR-seq, we reveal multiple intestinal chemosensory pathways. Among these, we determine that a cyclic fatty acid promotes serotonin production from enterochromaffin cells via olfactory receptor OR51E1. Two additional gut microbe-derived molecules, a β-carboline and 6-hydroxynicotinic acid (6-HNA), function as agonists for GPR35, a receptor linked to inflammatory bowel disease (IBD). The IBD-associated GPR35 risk variant, T108M, shows aberrant responses to 6-HNA, while Enterocloster bolteae, a species increased in IBD, generates high levels of 6-HNA. This approach provides an accelerated path to mapping critical chemosensory pathways and host physiological responses.
中文摘要:生物体对环境条件变化的反应依赖信息传递系统来感知信号并引发适当应答。G蛋白偶联受体(GPCRs)包括嗅觉受体,是识别环境线索的最大受体家族,人类基因组中超过800个基因。利用多重GPCR报告系统GPCR-seq筛选肠道代谢物和天然产物文库,揭示多条肠道化学感知通路。其中,一种环状脂肪酸经嗅觉受体OR51E1促进肠嗜铬细胞产生5-羟色胺。另外两种肠道微生物来源分子β-咔啉和6-羟基烟酸(6-HNA)作为GPR35的激动剂,GPR35与炎症性肠病(IBD)相关。IBD相关GPR35风险变异T108M对6-HNA表现出异常反应,而在IBD中增多的Enterocloster bolteae可产生高水平6-HNA。该方法为绘制关键化学感知通路和宿主生理反应提供了加速路径。
Critical reviews in food science and nutrition IF 10.6 2026-10-29 PMID: 42954296
Gut ecosystem homeostasis depends on coordinated interactions among commensal microorganisms, the mucosal barrier, and the immune system. Conventional prebiotics rely on selective utilization by host microorganisms, but their efficacy is shaped by baseline microbiota and disease-associated ecological constraints. Plant-derived exosome-like nanoparticles (PELNs) are naturally occurring membrane-bound nanoparticles characterized by source-dependent lipid interfaces and associated molecular components, including small RNAs, proteins, polysaccharides, and plant-derived metabolites. We evaluate selected PELNs within a provisional "candidate nano-prebiotic" framework that allows particle- or component-mediated mechanisms to coexist with microbial utilization of fermentable components without implying equivalence to consensus-defined prebiotics. We critically assess evidence for microbe-directed and host-mediated effects on microbial functions, microbiota-derived metabolites, epithelial barrier integrity, and mucosal immunity, particularly in inflammatory bowel disease (IBD). Current evidence remains heterogeneous and predominantly preclinical, with major uncertainties regarding particle identity, component-specific causality, in vivo fate, microbiota dependence, dose plausibility, and mechanistic generalizability. We further define conceptual boundaries among PELNs, conventional prebiotics, and engineered nano-prebiotics and identify priorities for standardization, causal testing, food-relevant exposure assessment, safety evaluation, and mechanistically informed human studies.
中文摘要:肠道生态系统稳态依赖共生微生物、黏膜屏障与免疫系统之间的协同互作。传统益生元依赖宿主微生物的选择性利用,但其效果受基线微生物群和疾病相关生态限制影响。植物来源外泌体样纳米颗粒(PELNs)是天然存在的膜结合纳米颗粒,具有来源依赖性脂质界面及相关分子组分,包括小RNA、蛋白质、多糖和植物来源代谢物。我们在暂定的「候选纳米益生元」框架内评估所选PELNs,该框架允许颗粒或组分介导的机制与微生物对可发酵组分的利用并存,但不意味着其等同于共识定义的益生元。我们批判性评估微生物导向和宿主介导效应方面的证据,涉及微生物功能、微生物群来源代谢物、上皮屏障完整性和黏膜免疫,尤其在炎症性肠病(IBD)中。现有证据仍异质且以临床前为主,在颗粒身份、组分特异性因果关系、体内命运、微生物群依赖性、剂量合理性及机制可推广性方面存在重大不确定性。我们进一步界定PELNs、传统益生元和工程化纳米益生元之间的概念边界,并确定标准化、因果检验、食品相关暴露评估、安全性评价和机制指导的人体研究方面的优先事项。
Immunity IF 30.6 2026-10-26 PMID: 42933395
Subsets of intestinal CD4+ T cells directly recognize commensal bacteria and coordinate tolerance versus protective immunity. Our limited understanding of CD4+ T cell specificities and corresponding functional phenotypes has created a barrier to deciphering the mechanisms of mucosal homeostasis and inflammation mediated by the adaptive immune system. To address this, we leveraged an immunodominant Bacteroidetes epitope in SusC to perform single-cell profiling of the SusC-specific and total CD4+ T cell landscapes in intestinal tissues of patients with inflammatory bowel disease (IBD). By analyzing phenotypes and T cell receptor specificities in parallel, we uncovered phenotypic diversification of T helper 17 (Th17) cells in IBD and identified an epithelial-localized, SusC-reactive Th17 subset that is BACH2lo, GZMAhi, and expresses the costimulatory receptor TMIGD2. Together, our results highlight the utility of tracking commensal-specific T cell responses to define specialized subsets of Th17 cells associated with loss of tolerance to the microbiome.
中文摘要:肠道CD4+ T细胞的不同亚群可直接识别共生细菌,并协调免疫耐受与保护性免疫。对CD4+ T细胞特异性及其对应功能表型认识有限,阻碍了解析适应性免疫介导的黏膜稳态与炎症机制。为此,我们利用SusC中一个免疫优势拟杆菌门表位,对炎症性肠病(IBD)患者肠道组织中的SusC特异性CD4+ T细胞及总CD4+ T细胞进行单细胞图谱分析。平行分析表型与T细胞受体特异性,揭示IBD中辅助性T细胞17(Th17)的表型多样化,并鉴定出一个定位于上皮、对SusC反应、BACH2lo、GZMAhi且表达共刺激受体TMIGD2的Th17亚群。结果说明,追踪共生菌特异性T细胞反应有助于界定与微生物组耐受丧失相关的特化Th17亚群。

2炎症性肠病 (2篇)

基础研究 (2篇)

Clinical reviews in allergy & immunology IF 11.5 2026-10-31 PMID: 42963501
Mas-related G protein-coupled receptor X2 (MRGPRX2) is a mast-cell-enriched receptor that mediates immunoglobulin E-independent activation by structurally diverse neuropeptides, host-defense peptides, microbial products, and selected cationic drugs. Its biology links tissue stress and neuroimmune signaling to degranulation, vascular responses, pruritus, barrier dysfunction, and inflammatory amplification, but the extent to which individual diseases depend on this pathway remains uncertain. The strongest clinical rationale begins with non-IgE-mediated immediate drug hypersensitivity, for which MRGPRX2 provides a direct mechanistic framework, although rocuronium illustrates the need to distinguish human MRGPRX2 pharmacology from murine Mrgprb2 and from IgE-mediated perioperative allergy. In atopic dermatitis, preclinical and human skin data support a potential amplifier role in type 2 inflammation and itch, but a randomized phase 2b study of EVO756 did not demonstrate efficacy in an unselected population. In chronic urticaria, challenge, biomarker, and genetic studies suggest an MRGPRX2-responsive subgroup within a heterogeneous disease, whereas a randomized phase 2b study of EVO756 in unselected chronic spontaneous urticaria was also negative despite earlier pharmacodynamic activity. Ulcerative colitis provides additional human tissue evidence for an MRGPRX2-associated mast-cell circuit, although murine Mrgprb2 studies show context-dependent protective and pathogenic effects. Emerging evidence in chronic prurigo, allergic contact dermatitis, asthma, mastocytosis, rheumatoid arthritis, synovial inflammation, and neurogenic inflammation is also considered, with explicit separation of human observations from mouse-model evidence. We integrate these findings with receptor pharmacology and early clinical development, emphasizing evidence hierarchy, validated biomarker needs, patient selection, tissue target engagement, safety, and trial design. Current data support MRGPRX2 as an investigational endotype-defining pathway rather than a universal driver of allergic or immune-mediated disease.
中文摘要:Mas相关G蛋白偶联受体X2(MRGPRX2)是一种富集于肥大细胞的受体,可被结构多样的神经肽、宿主防御肽、微生物产物及部分阳离子药物激活,介导不依赖免疫球蛋白E的肥大细胞活化。其生物学将组织应激与神经免疫信号连接至脱颗粒、血管反应、瘙痒、屏障功能障碍和炎症放大,但各疾病在多大程度上依赖该通路仍不确定。最强的临床依据始于非IgE介导的速发型药物超敏反应,MRGPRX2为此提供了直接机制框架,不过罗库溴铵的例子说明需区分人MRGPRX2药理学、小鼠Mrgprb2以及IgE介导的围手术期过敏。在特应性皮炎中,临床前与人皮肤数据支持其在2型炎症和瘙痒中的潜在放大作用,但EVO756的一项随机2b期研究未在未选择人群中显示疗效。在慢性荨麻疹中,激发试验、生物标志物和遗传学研究提示异质性疾病中存在MRGPRX2反应性亚组,而EVO756在未选择的慢性自发性荨麻疹中开展的随机2b期研究尽管早期有药效学活性,结果仍为阴性。溃疡性结肠炎提供了额外的人体组织证据,支持MRGPRX2相关的肥大细胞环路,但小鼠Mrgprb2研究显示其保护性或致病性效应取决于背景。慢性痒疹、过敏性接触性皮炎、哮喘、肥大细胞增多症、类风湿关节炎、滑膜炎症和神经源性炎症的新兴证据亦被讨论,并明确区分人体观察与小鼠模型证据。我们将这些发现与受体药理学及早期临床开发相结合,强调证据层级、经过验证的生物标志物需求、患者选择、组织靶点结合、安全性和试验设计。当前数据支持将MRGPRX2视为一种研究性、可界定内型的通路,而非过敏性或免疫介导疾病的普遍驱动因素。
Nature IF 56.1 2026-10-28 PMID: 42951970
Understanding how genetic variation shapes gene regulation at single-cell resolution is crucial for elucidating complex disease mechanisms1, but has been limited by the lack of large-scale single-cell multi-omics data2-4. Here we present single-cell assay for transposase-accessible chromatin with sequencing of 3.5 million peripheral blood mononuclear cells from 1,042 donors with matched whole-genome sequencing. Across 28 immune cell types, we tested 440,996 chromatin accessibility peaks and identified 243,225 chromatin accessibility quantitative trait loci (caQTLs) at 100,483 peaks, 60% of them cell-type specific. Rare variant analysis identified 38,161 associated peaks, with predicted transcription factor-binding disruption implicated at individual loci. Colocalization with expression QTLs (eQTLs) from single-cell RNA sequencing data (5.4 million peripheral blood mononuclear cells)5 defined 28,834 candidate cis-regulatory elements. Across genome-wide association studies for 16 diseases and 44 blood traits, caQTLs colocalized 4.5-22.6% more signals than eQTLs alone. Cell-type-specific and tissue-specific context, distal effects and multi-causal-variant models raised genome-wide association study-eQTL concordance from approximately 16% to approximately 65%. Cell state further modulates genetic effects, with 27% of over 200,000 caQTL-cell-state interactions lacking a main effect. At the inflammatory bowel disease risk gene ADCY7, accessibility effects varied with genotype and G protein-mediated pathway activity in CD4+ T cells. A graph neural network trained on both eQTL and caQTL layers inferred peak-gene links in unpaired multiome data with up to 17.2% higher accuracy than QTL-agnostic data, uncovering 128 additional transcription factor-target pairs (22% increase). Together, these results show that genetic variants shape chromatin accessibility in a cell-type-specific and cell-state-specific manner, influencing immune function and disease risk.
中文摘要:在单细胞分辨率下理解遗传变异如何塑造基因调控,对阐明复杂疾病机制至关重要,但缺乏大规模单细胞多组学数据限制了相关研究。该研究对来自1,042名供者的350万个外周血单个核细胞进行单细胞转座酶可及染色质测序,并匹配全基因组测序。在28种免疫细胞类型中,检测了440,996个染色质可及性峰,在100,483个峰上鉴定出243,225个染色质可及性数量性状位点(caQTL),其中60%具有细胞类型特异性。稀有变异分析鉴定出38,161个相关峰,预测的转录因子结合破坏在单个位点中有所体现。与单细胞RNA测序数据(540万个外周血单个核细胞)中的表达数量性状位点(eQTL)共定位,定义了28,834个候选顺式调控元件。在针对16种疾病和44种血液性状的全基因组关联研究中,caQTL比单独eQTL多共定位4.5%至22.6%的信号。细胞类型特异性和组织特异性背景、远端效应及多因果变异模型将全基因组关联研究与eQTL的一致性从约16%提高到约65%。细胞状态进一步调节遗传效应,在超过200,000个caQTL与细胞状态交互中,27%缺乏主效应。在炎症性肠病风险基因ADCY7处,CD4+ T细胞中的可及性效应随基因型和G蛋白介导通路活性而变化。一个同时在eQTL和caQTL层训练的图神经网络在未配对多组学数据中推断峰-基因连接,准确率比不利用QTL信息的数据最高提高17.2%,并发现128个额外的转录因子-靶标对(增加22%)。这些结果表明,遗传变异以细胞类型特异性和细胞状态特异性方式塑造染色质可及性,影响免疫功能和疾病风险。

3肠易激/IBS/功能性胃肠病 (2篇)

临床研究 (1篇)

EBioMedicine IF 11.2 2026-10-30 PMID: 42962555
The infant gut microbiome undergoes rapid maturation that shapes lifelong gastrointestinal health. Although adults with irritable bowel syndrome (IBS) show characteristic microbial and metabolic alterations, it remains unclear whether these differences precede disease onset. Here, microbiome composition and function in infancy were prospectively associated with future IBS development. Stool samples collected from the All Babies in Southeast Sweden (ABIS) cohort at a mean age of 12.4 (±1.5) months, were analysed using a nested case-control design. Cases included future IBS and/or pelvic and abdominal pain, with the average time between age at stool collection and diagnosis being 11.8 (±5.2) years and a mean age at diagnosis of 12.8 (±5.2) years. Microbial composition was profiled with 16S rRNA gene sequencing (n = 396). Data were processed with DADA2, taxonomically assigned using SILVA database, and predicted functionally with PICRUSt2. Descriptive statistics were analysed using χ2 or Fisher's exact test, global differences with PERMANOVA, differential abundance with ANCOM-BC2, and pathway enrichment with GSEA. Infants with future IBS risk demonstrated microbial divergence, marked by depletion of short-chain fatty acid producers and expansion of facultative and mucosa-disruptive taxa. Inferred functional profiles exhibited reduced fermentative capacity, greater respiratory potential, accelerated degradation of neuroactive aromatic amines, and case-enrichment of cytochrome bc1 complex respiratory unit. Gut microbiome dysbiosis in infants with IBS risk is present many years prior to diagnosis and includes early disruptions in fermentation, redox balance, and amine metabolism that potentially compromise epithelial resilience and promote visceral hypersensitivity. Early detection of microbiome dysbiosis suggests probiotic-based interventions. Barndiabetesfonden; Swedish Council for Working Life and Social Research; Swedish Research Council; Östgöta Brandstodsbolag; Medical Research Council of Southeast Sweden; JDRF-Wallenberg Foundation; Linköping University; Horizon Europe INITIALISE grant.
中文摘要:婴儿肠道微生物组快速成熟,并塑造终生胃肠健康。尽管成人肠易激综合征(IBS)患者存在特征性的微生物和代谢改变,这些差异是否先于疾病发生仍不清楚。该研究将婴儿期微生物组组成与功能同未来IBS发生进行前瞻性关联。研究采用巢状病例对照设计,分析瑞典东南部所有婴儿(ABIS)队列在平均12.4(±1.5)月龄采集的粪便样本。病例包括未来发生IBS和/或盆腔与腹部疼痛者,粪便采集至诊断的平均时间为11.8(±5.2)年,平均诊断年龄为12.8(±5.2)岁。微生物组成通过16S rRNA基因测序分析(n=396)。数据用DADA2处理,使用SILVA数据库进行分类学注释,并用PICRUSt2预测功能。描述性统计采用χ2或Fisher精确检验,整体差异采用PERMANOVA,差异丰度采用ANCOM-BC2,通路富集采用GSEA。未来有IBS风险的婴儿表现出微生物群分化,特征为短链脂肪酸产生菌减少以及兼性类群和黏膜破坏性类群扩张。推断的功能谱显示发酵能力降低、呼吸潜能升高、神经活性芳香胺降解加速,以及细胞色素bc1复合体呼吸单元在病例组富集。有IBS风险的婴儿在诊断前多年即存在肠道微生物群失调,并包括发酵、氧化还原平衡和胺代谢的早期紊乱,这些紊乱可能削弱上皮韧性并促进内脏高敏感。微生物群失调的早期检出提示可考虑基于益生菌的干预。资助来源:Barndiabetesfonden;瑞典工作生活与社会研究委员会;瑞典研究委员会;Östgöta Brandstodsbolag;瑞典东南部医学研究委员会;JDRF-Wallenberg基金会;林雪平大学;Horizon Europe INITIALISE grant。

基础研究 (1篇)

Critical reviews in food science and nutrition IF 10.6 2026-10-29 PMID: 42955268
Autism Spectrum Disorder (ASD) is a complex neurodevelopmental condition, frequently comorbid with heterogeneous gastrointestinal (GI) pathologies, including Irritable Bowel Syndrome (IBS), Inflammatory Bowel Disease (IBD), and functional motility disorders. Emerging evidence implicates the microbiota-gut-brain axis in the pathogenesis of these GI anomalies. Dietary polyphenols, characterized by potent antioxidant, anti-inflammatory, and neuromodulatory properties, represent a promising candidate approach for exploring the management of these comorbid conditions. This review critically examines the proposed molecular mechanisms by which specific phenolic compounds (e.g., resveratrol, quercetin and curcumin) may mitigate GI symptoms in ASD. Mechanistically, preclinical evidence suggests that polyphenols may help restore intestinal barrier integrity by upregulating tight junction proteins, suppress mucosal inflammation via the downregulation of Nuclear Factor Kappa B (NF-κB)/NOD-like Receptor Family Pyrin Domain Containing 3(NLRP3) pathways, and regulate gut motility through enteric neurotransmitter modulation. However, direct clinical efficacy in individuals with ASD remains largely unproven. Future clinical directions are proposed, focusing on the incorporation of low-fermentable oligosaccharides, disaccharides, monosaccharides, and polyols (FODMAPs) natural food matrices and the development of controlled food fortification strategies over isolated high-dose supplementation. This work provides a theoretical foundation and a concise roadmap for advancing polyphenol-based dietary interventions in the management of GI pathophysiology in ASD.
中文摘要:自闭症谱系障碍(ASD)是一种复杂的神经发育状况,常合并异质性胃肠道(GI)病理,包括肠易激综合征(IBS)、炎症性肠病(IBD)和功能性运动障碍。新出现的证据提示微生物群-肠-脑轴参与这些GI异常的发病机制。膳食多酚具有强抗氧化、抗炎和神经调节特性,是探索这些共病管理的候选途径。本综述批判性审视特定酚类化合物(如白藜芦醇、槲皮素和姜黄素)可能缓解ASD中GI症状的拟议分子机制。在机制层面,临床前证据提示多酚可能通过上调紧密连接蛋白帮助恢复肠道屏障完整性,通过下调核因子κB(NF-κB)/NOD样受体家族含pyrin结构域3(NLRP3)通路抑制黏膜炎症,并通过调节肠神经递质调控胃肠动力。然而,在ASD个体中的直接临床疗效在很大程度上仍未得到证实。文中提出未来临床方向,重点是将低可发酵寡糖、二糖、单糖和多元醇(FODMAPs)天然食物基质纳入,以及发展受控食品强化策略而非分离高剂量补充。这项工作为推进基于多酚的膳食干预以管理ASD中的GI病理生理提供了理论基础和简明路线图。

4病毒性肝炎 (2篇)

临床研究 (1篇)

Clinical and molecular hepatology IF 21.7 2026-10-27 PMID: 42935235
Glucagon-like peptide-1 receptor agonists (GLP-1RA) are a novel class of anti-diabetic drugs that can treat obesity and type 2 diabetes (T2D). T2D and chronic viral hepatitis (CVH) frequently coexist and worsen liver and non-liver outcomes, but effective pharmacological therapies are limited. We aimed to evaluate the effect of GLP-1RA on liver and non-liver complications among patients with T2D and CVH in the United States. Patients with T2D and CVH initiating GLP-1RA were included (2013-2022) in Merative™ Marketscan® Research Databases. Primary outcomes included (1) hepatocellular carcinoma (HCC) and cirrhosis, and (2) cardiovascular disease (CVD), chronic kidney disease (CKD), and non-liver cancer. Cox proportional hazards models were conducted to estimate hazard ratio (HR) and 95% confidence interval (CI). A total of 9,499 patients with T2D and CVH were included after 1:4 propensity score matching. Compared with non-GLP-1RA (N=7,366), GLP-1RA use (N=2,133) was associated with significantly lower risks of any liver-related outcomes (HR 0.71, 95% CI 0.57-0.87; P=0.001), HCC (HR 0.53, 95% CI 0.31-0.93; P=0.028), cirrhosis (HR 0.70, 95% CI 0.56-0.86; P<0.001), CKD (HR 0.67, 95% CI 0.53-0.84; P<0.001). A trend toward a lower risk of CVD (HR 0.82, 95% CI 0.66-1.03; P=0.089) and non-liver cancer (HR 0.73, 95% CI 0.53-1.01; P=0.055) was observed among GLP-1RA users, although the association did not reach statistical significance. GLP-1RA use was associated with lower risks of cirrhosis, HCC, and CKD among patients with T2D and CVH, with nonsignificant trends toward lower risks of CVD and non-liver cancer.
中文摘要:胰高血糖素样肽-1受体激动剂(GLP-1RA)是一类新型抗糖尿病药物,可治疗肥胖和2型糖尿病(T2D)。T2D与慢性病毒性肝炎(CVH)常同时存在,并加重肝脏和非肝脏结局,但有效的药物治疗有限。研究旨在评估美国T2D合并CVH患者中GLP-1RA对肝脏和非肝脏并发症的影响。纳入2013—2022年在Merative™ Marketscan® Research Databases中开始使用GLP-1RA的T2D合并CVH患者。主要结局包括(1)肝细胞癌(HCC)和肝硬化,(2)心血管疾病(CVD)、慢性肾脏病(CKD)和非肝脏肿瘤。采用Cox比例风险模型估计风险比(HR)和95%置信区间(CI)。经1:4倾向评分匹配后,共纳入9,499例T2D合并CVH患者。与非GLP-1RA组(N=7,366)相比,使用GLP-1RA(N=2,133)与任何肝脏相关结局风险显著降低相关(HR 0.71,95% CI 0.57-0.87;P=0.001)、HCC风险降低(HR 0.53,95% CI 0.31-0.93;P=0.028)、肝硬化风险降低(HR 0.70,95% CI 0.56-0.86;P<0.001)、CKD风险降低(HR 0.67,95% CI 0.53-0.84;P<0.001)。GLP-1RA使用者中观察到CVD风险(HR 0.82,95% CI 0.66-1.03;P=0.089)和非肝脏肿瘤风险(HR 0.73,95% CI 0.53-1.01;P=0.055)有降低趋势,但关联未达到统计学显著性。在T2D合并CVH患者中,使用GLP-1RA与肝硬化、HCC和CKD风险降低相关,CVD和非肝脏肿瘤风险降低呈非显著趋势。

基础研究 (1篇)

ACS sensors IF 10.9 2026-10-29 PMID: 42956092
Nucleic acid amplification commonly relies on fluorescent labels and electrically driven thermal control, limiting simplicity, scalability, and remote deployment. Here, we establish a label-free optical strategy based on amplification-associated refractive-index (RI) evolution within a confined optothermal microcavity. During amplification, the accumulation of nucleic acid products alters the composition and molecular polarizability of the reaction medium, contributing to a progressive increase in its effective RI. This bulk RI change is converted into interferometric phase accumulation under thermally stabilized conditions, enabling real-time optical readout without labels. We implement this strategy in a 0.94 nL fiber Fabry-Perot microcavity that integrates localized optothermal regulation and phase-sensitive interrogation within a single optical pathway. The confined geometry enables rapid optothermal heating, reaching a 1 °C temperature rise in 15 ms, nearly three orders of magnitude faster than conventional electrical heating. Using hepatitis B virus (HBV) DNA as a model target, we achieve a detection limit of 5.24 copies/nL and quantitative agreement with fluorescence-based assays, while isothermal amplification reduces the total assay time by approximately 50% relative to commercial qPCR. Frequency-division multiplexing enables parallel multi-target analysis, while stable transmission is maintained over 20 km fiber links. Our results establish amplification-associated RI evolution as a promising label-free transduction mechanism for fiber-integrated molecular diagnostics.
中文摘要:核酸扩增通常依赖荧光标记和电驱动热控制,限制了简便性、可扩展性和远程部署。本研究建立了一种基于受限光热微腔内扩增相关折射率(RI)演变的无标记光学策略。扩增过程中,核酸产物的积累改变反应介质的组成和分子极化率,使其有效RI逐步升高。在热稳定条件下,这种体相RI变化被转换为干涉相位累积,从而无需标记即可实时光学读出。我们在0.94 nL光纤法布里-珀罗微腔中实现该策略,将局部光热调控与相位敏感探测集成于单一光路。受限几何结构实现快速光热加热,15 ms内升温1 °C,比传统电加热快近三个数量级。以乙型肝炎病毒(HBV)DNA为模型靶标,检测限达5.24 copies/nL,并与荧光法测定定量一致;等温扩增使总检测时间较商用qPCR缩短约50%。频分复用支持并行多靶标分析,并在20 km光纤链路上保持稳定传输。结果表明,扩增相关RI演变可作为光纤集成分子诊断的有前景无标记换能机制。

5食管癌 (1篇)

临床研究 (1篇)

Journal of advanced research IF 17.1 2026-10-30 PMID: 42962916
Esophageal cancer (EC) remains a significant public health burden in China. Current diagnostics modalities such as endoscopy and imaging are invasive, poorly accessible, or insensitive for early-stage cases. DNA methylation alterations in circulating free DNA (cfDNA) are promising for non-invasive cancer detection. We aimed to develop and validate a methylation PCR-based assay for EC detection using EC-specific DNA methylation targets. Here, we report myESCAP, a PCR-based assay that amplifies and quantifies levels of EC-specific methylation in cfDNA METHODS: We conducted a multi-center, retrospective case-control study with 489 EC cases and 555 non-malignant controls (benign esophageal/gastric diseases or asymptomatic) to develop myESCAP, a methylation-specific PCR assay containing 11 EC-specific methylation markers from our previous genome-wide methylation screening, selected for strong discriminative performance and PCR compatibility. cfDNA was collected, bisulfite-converted, and tested by myESCAP, and results were analyzed by six modeling strategies (generalized linear model, k-nearest neighbors, C5.0 decision tree, gradient boosting machine, random forest, support vector machine) to train EC-prediction models using 347 EC cases and 349 non-malignant controls, and validated in 142 EC cases and 206 controls. All myESCAP markers demonstrated significant differential methylation between ECs and non-malignant controls, with adjusted p values between 5.8×10⁻3 and 3.1×10⁻88. The six models showed robust performance in the training cohort (average AUC = 0.835, average sensitivity = 76.13%, average specificity = 90.88%). They maintained performance in the validation cohort (average AUC = 0.823, average sensitivity = 75.59%, average specificity = 89%). Specifically, for stage I cases, myESCAP had an average sensitivity of 47.2%, highlighting the challenge of early detection with limited circulating tumor DNA and the need for further optimization. myESCAP accurately differentiated EC from non-malignant controls. The six models collectively confirm myESCAP's robustness and clinical potential as a cost-effective, non-invasive diagnostic tool for EC.
中文摘要:食管癌在中国仍是重要公共卫生负担。内镜和影像等现有诊断方式具有侵入性、可及性差或对早期病例不敏感。循环游离DNA(cfDNA)中的DNA甲基化改变为非侵入性癌症检测提供了有希望的方向。研究旨在利用食管癌特异性DNA甲基化靶点开发并验证一种基于甲基化PCR的食管癌检测方法。myESCAP是一种基于PCR的方法,可扩增并定量cfDNA中食管癌特异性甲基化水平。方法:开展多中心回顾性病例对照研究,纳入489例食管癌病例和555例非恶性对照(良性食管/胃疾病或无症状者),以开发myESCAP。该甲基化特异性PCR检测包含来自既往全基因组甲基化筛查的11个食管癌特异性甲基化标志物,选择依据为较强判别性能和PCR兼容性。收集cfDNA,进行亚硫酸氢盐转化,并用myESCAP检测;采用六种建模策略(广义线性模型、k近邻、C5.0决策树、梯度提升机、随机森林、支持向量机)分析结果,以347例食管癌病例和349例非恶性对照训练食管癌预测模型,并在142例食管癌病例和206例对照中验证。所有myESCAP标志物在食管癌与非恶性对照之间均显示显著差异甲基化,校正p值介于5.8×10⁻3至3.1×10⁻88。六种模型在训练队列中表现稳健(平均AUC=0.835,平均灵敏度=76.13%,平均特异度=90.88%)。在验证队列中保持性能(平均AUC=0.823,平均灵敏度=75.59%,平均特异度=89%)。对于I期病例,myESCAP平均灵敏度为47.2%,凸显循环肿瘤DNA有限时早期检测的挑战及进一步优化需求。myESCAP能准确区分食管癌与非恶性对照。六种模型共同证实myESCAP作为经济、非侵入性食管癌诊断工具的稳健性和临床潜力。

6肝病/肝硬化 (1篇)

基础研究 (1篇)

Food chemistry IF 10.4 2026-10-30 PMID: 42685422
Global food safety requires reliable biosensors in complex matrices. Yet, conventional single-signal electrochemical biosensors suffer from high inter-electrode variability (RSD <12.14%) and low accuracy (<87.84%) due to common-mode signal fluctuations. This study presents a ratiometric biosensor with a dual-electrode design that enables calculation of the current ratio (IWE2/IWE1) between a formaldehyde dehydrogenase-functionalized sensing electrode and an inert graphene reference to mitigate systemic fluctuations. This self-calibrating configuration reduced variability (RSD of 6.92%), improved accuracy (>97.29%), and minimized interference effects (from 7.54% to 1.52%). Spanning a linear range of 0.02-0.50 mM with a LOD of 0.004 mM, the biosensor achieved 97.22-103.87% recovery in coffee samples (RSD = 0.21%). Validation against the Nash assay showed strong correlation (R2 = 0.995) with comparable accuracy at 0.10-0.50 mM concentrations, yet up to nine-fold higher accuracy at 0.02 mM (p < 0.05), confirming its superior suitability for practical application in food safety monitoring.
中文摘要:全球食品安全需要在复杂基质中使用可靠的生物传感器。传统单信号电化学生物传感器受共模信号波动影响,存在较高的电极间变异(RSD <12.14%)和较低准确度(<87.84%)。本研究提出一种双电极设计的比率型生物传感器,通过计算甲醛脱氢酶功能化传感电极与惰性石墨烯参比电极之间的电流比(IWE2/IWE1),降低系统性波动。该自校准构型将变异降至RSD 6.92%,准确度提高至>97.29%,并将干扰效应从7.54%降至1.52%。传感器线性范围为0.02–0.50 mM,检出限为0.004 mM,在咖啡样品中回收率为97.22–103.87%(RSD = 0.21%)。与Nash法验证显示强相关性(R2 = 0.995),在0.10–0.50 mM浓度下准确度相当,而在0.02 mM下准确度最高提高九倍(p < 0.05),证实其更适合食品安全监测的实际应用。

7内镜/ESD/ERCP (1篇)

基础研究 (1篇)

Science robotics IF 25.5 2026-10-28 PMID: 42950062
Diagnosing and treating small intestinal disorders such as bleeding, inflammatory bowel disease, and tumors present challenges because of limited access to this anatomical compartment. We present BIOSENTER, a bioinspired soft enteroscopic robot for deep procedures in the small intestine that addresses locomotion, steering, and intervention constraints of existing soft robotic systems. BIOSENTER features a hollow cylinder architecture comprising a linearly deformable soft pneumatic actuator as the body, two radially expandable soft pneumatic actuators wrapped with kirigami sleeves as the head and tail, a central hollow channel for accessory endoscopic tools, and a control box for navigation. Inspired by snake locomotion, the robotic body incorporates a fiber-reinforced actuator with four embedded inflatable chambers, enabling steering and axial expansion. The dynamic kirigami sleeves generate an anchoring force of ∼1.5 newtons on intestinal mucosa while requiring substantially less radial expansion than the corresponding nonkirigami configuration. A reinforced central channel supports tool passage for diagnostic and therapeutic interventions. The control box enables locomotion and steering at autonomous speeds of ∼100 millimeters per minute in vitro and ∼43 millimeters per minute in tissue-covered tubing. BIOSENTER successfully navigated the collapsed, tortuous small intestine for 2 meters in 11 minutes, with gentle forward pushing forces of 2.2 to 6.4 newtons in pig studies. In vivo pig studies demonstrated technical feasibility of tissue biopsy, localized fluid delivery as a model for future drug administration, and real-time visualization of the deep intestine, without macroscopic overdistention or visible tissue damage under the tested conditions.
中文摘要:小肠出血、炎症性肠病和肿瘤等疾病的诊治受限于该解剖部位难以到达。BIOSENTER是一种面向小肠深部操作的仿生软体内镜机器人,针对现有软体机器人系统在运动、转向和介入方面的限制进行设计。BIOSENTER采用中空圆柱结构,以可线性变形的软体气动驱动器作为主体,以两个包裹剪纸套筒的径向可扩张软体气动驱动器作为头端和尾端,设有供附属内镜工具通过的中心中空通道,并配有用于导航的控制箱。受蛇类运动启发,机器人主体采用纤维增强驱动器,内置四个可充气腔室,实现转向和轴向扩张。动态剪纸套筒在肠黏膜上产生约1.5牛的锚定力,同时所需径向扩张明显小于相应的非剪纸结构。增强中心通道支持诊断和治疗工具通过。控制箱使机器人以约100毫米/分钟的自主速度在体外运动并转向,在覆有组织的管道中约为43毫米/分钟。BIOSENTER在猪研究中成功通过塌陷、迂曲的小肠2米,用时11分钟,前向推力为2.2至6.4牛,较为轻柔。体内猪研究证明组织活检、局部液体递送(作为未来给药的模型)和深部肠道实时可视化在技术上可行,在测试条件下未出现宏观过度扩张或可见组织损伤。

8GERD/幽门螺杆菌 (1篇)

临床研究 (1篇)

Drugs IF 14.7 2026-10-28 PMID: 42946944
The pharmacological control of gastric acid secretion has evolved substantially over the past five decades, yet clinically important limitations remain with delayed-release proton pump inhibitors (PPIs), including delayed onset of action, meal dependency, nocturnal acid breakthrough, and variable intragastric pH control. Potassium-competitive acid blockers (P-CABs) represent a major advance in antisecretory therapy by providing rapid, potent, sustained, and meal-independent inhibition of the gastric H+,K+-ATPase through a reversible mechanism of action. Among currently available P-CABs, fexuprazan is a relatively recent agent for which an expanding body of pharmacological and clinical evidence has become available. This review critically examines its pharmacology, experimental biology, and clinical efficacy, with particular emphasis on gastroesophageal reflux disease (GERD) and Helicobacter pylori infection. Randomized controlled trials and real-world studies demonstrate that fexuprazan is non-inferior to esomeprazole in healing erosive esophagitis, with evidence of rapid symptom improvement, effective nocturnal symptom control, and greater dosing flexibility. Emerging data also suggest potential benefit in extra-esophageal manifestations of GERD. Experimental studies indicate anti-inflammatory, antioxidant, and epithelial barrier-protective properties, although their clinical relevance remains to be established. In H. pylori infection, the profound and sustained intragastric pH elevation achieved with P-CABs may enhance eradication therapy, and fexuprazan-based triple, quadruple, and dual regimens have shown promising efficacy and tolerability. Overall, current evidence indicates that fexuprazan is an effective and well-tolerated P-CAB that may overcome some of the limitations of conventional PPIs, while ongoing comparative and long-term studies will further define its place in the management of acid-related disorders.
中文摘要:胃酸分泌的药理学控制在过去五十年间已有显著进展,但延迟释放型质子泵抑制剂(PPIs)仍存在临床重要局限,包括起效延迟、依赖进餐、夜间酸突破以及胃内pH控制不稳定。钾离子竞争性酸阻滞剂(P-CABs)通过可逆机制对胃H+,K+-ATP酶产生快速、强效、持久且不依赖进餐的抑制,是抑酸治疗的重要进展。在现有P-CABs中,非苏拉生是相对较新的药物,其药理学和临床证据不断积累。本综述批判性审视其药理学、实验生物学和临床疗效,重点放在胃食管反流病(GERD)和幽门螺杆菌感染。随机对照试验和真实世界研究表明,非苏拉生在愈合糜烂性食管炎方面不劣于埃索美拉唑,并有证据显示其可快速改善症状、有效控制夜间症状以及具有更大的给药灵活性。新出现的数据还提示其可能对GERD的食管外表现有益。实验研究显示其具有抗炎、抗氧化和上皮屏障保护特性,但这些特性的临床相关性仍有待确定。在幽门螺杆菌感染中,P-CABs实现的显著且持续胃内pH升高可能增强根除治疗,基于非苏拉生的三联、四联和双联方案已显示出有前景的疗效和耐受性。当前证据表明,非苏拉生是一种有效且耐受性良好的P-CAB,可能克服传统PPIs的部分局限,正在进行的比较研究和长期研究将进一步确定其在酸相关疾病管理中的地位。

9胰腺癌 (1篇)

临床研究 (1篇)

Cell death & disease IF 12.2 2026-10-27 PMID: 42957626
The biological and clinical significance of the intratumoral microbiota in pancreatic ductal adenocarcinoma (PDAC) remains poorly defined. Using oncogenic Kras-driven mouse models of pancreatic tumorigenesis and human pancreatic tissue from patients with non-metastatic PDAC treated with neoadjuvant (n = 62) or adjuvant therapy (n = 101), along with samples from intraductal papillary mucinous neoplasms (IPMN, n = 24), chronic pancreatitis (CP, n = 33), and healthy donors (n = 9), we determined tissue lipopolysaccharide (LPS), 16S rRNA sequencing, high-resolution quantitative multiplex immunofluorescence of autophagy markers (LAMP2, LC3B) and LPS, 16S rRNA fluorescence in situ hybridization (FISH) staining, and TLR4 signaling. In KrasCre mice, we identified significant bacterial accumulation in the pancreas, indicated by elevated LPS, increased FISH signals, enhanced TLR4 signaling, and activation of autophagy. Administration of exogenous LPS further amplified autophagy and TLR4 signaling, supporting a mechanistic link between microbial sensing and autophagy. In human tissue, both adjuvant and neoadjuvant PDAC samples showed significantly increased bacterial alpha- and beta diversity compared with controls, while CP showed a similar enrichment pattern that IPMN lacks; the underlying microbial diversity differs fundamentally across these conditions. Increased LPS levels, along with elevated autophagy markers and abundant FISH-positive bacteria, support the presence of intratumoral bacteria. Across four independent transcriptomic datasets, PDAC samples showed elevated expression of bacteria-associated pathways (including TLR4) and autophagy-related genes. Clinically, higher autophagy-associated LAMP2-LC3B colocalization and increased densities of FISH-positive cells were independently associated with prolonged survival in both adjuvant and neoadjuvant or combined PDAC patients. Collectively, these findings link intratumoral microbial enrichment to increased autophagy-associated signaling and improved patient outcomes, suggesting that microbial signals within the tumor microenvironment were associated with favorable survival.
中文摘要:胰腺导管腺癌(PDAC)瘤内微生物群的生物学和临床意义仍不明确。我们使用致癌性Kras驱动的胰腺肿瘤发生小鼠模型,以及接受新辅助治疗(n=62)或辅助治疗(n=101)的非转移性PDAC患者胰腺组织、导管内乳头状黏液性肿瘤(IPMN,n=24)、慢性胰腺炎(CP,n=33)和健康供者(n=9)样本,检测了组织脂多糖(LPS)、16S rRNA测序、自噬标志物(LAMP2、LC3B)与LPS的高分辨率定量多重免疫荧光、16S rRNA荧光原位杂交(FISH)染色及TLR4信号。在KrasCre小鼠中,胰腺内可见明显细菌积聚,表现为LPS升高、FISH信号增强、TLR4信号增强和自噬激活。给予外源性LPS进一步放大了自噬和TLR4信号,支持微生物感知与自噬之间存在机制联系。在人类组织中,辅助治疗和新辅助治疗的PDAC样本细菌α多样性和β多样性均较对照组显著升高,CP呈现类似的富集模式,而IPMN缺乏这种模式;这些病变的基础微生物多样性存在根本差异。LPS水平升高、自噬标志物升高以及大量FISH阳性细菌,支持瘤内细菌的存在。在四个独立的转录组数据集中,PDAC样本中细菌相关通路(包括TLR4)和自噬相关基因的表达升高。在临床层面,较高的自噬相关LAMP2-LC3B共定位和更高的FISH阳性细胞密度,在辅助治疗、新辅助治疗或两者合并的PDAC患者中均与生存期延长独立相关。这些发现将瘤内微生物富集与自噬相关信号增强及患者结局改善联系起来,提示肿瘤微环境中的微生物信号与较好的生存相关。

10肝癌 (1篇)

基础研究 (1篇)

Journal of hepatology IF 40.1 2026-10-26 PMID: 42933735
Whether intestinal fungal dysbiosis contributes to hepatocellular carcinoma (HCC) progression and resistance to immune checkpoint inhibitors (ICIs) remains unclear. We investigated how gut Candida albicans influences HCC progression, immune remodeling, and response to ICI therapy. Fecal and tumor samples from patients with HCC, liver cirrhosis, and healthy controls were analyzed using ITS2 sequencing, immune profiling, and correlation analyses. Mechanistic studies focused on four complementary autochthonous murine HCC models and cell-based assays, integrating single-cell and bulk RNA sequencing, genetic and pharmacologic perturbations, Kaede photoconversion, fungal antigen recall assays, antifungal treatment, and anti-PD-1 therapy. Fecal C. albicans abundance was higher in HCC patients and was associated with advanced disease, shorter overall survival, and reduced durable clinical benefit. Across HCC models, C. albicans gavage increased tumor burden and induced a Th17/IL-17A-skewed microenvironment characterized by Trem2+ macrophage accumulation and impaired CD8+ T cell infiltration and function. Antifungal treatment attenuated tumor progression, whereas IL-17A blockade or deficiency largely abrogated C. albicans-associated tumor promotion. Mechanistically, IL-17A induced tumor-derived MCP-1 through ACT1-TRAF6-TAK1 signaling to recruit macrophages and upregulated PAI-1, which activated TGF-β/Smad3 signaling to promote an immunosuppressive Trem2+ macrophage state. These macrophages limited CD8+ T cell recruitment and effector function through coordinated CXCL10 repression and GAL-1 induction, while potentially reinforcing Th17 responses through IL-1β and IL-6. Kaede photoconversion demonstrated enhanced mesenteric lymph node-to-liver Th17 trafficking, while fungal antigen recall assays revealed preferential Th17 responsiveness to C. albicans. C. albicans also impaired anti-PD-1 efficacy in vivo, whereas antifungal treatment partially restored therapeutic responsiveness. Intestinal C. albicans promotes HCC progression and anti-PD-1 resistance through an IL-17A-Trem2+ macrophage circuit, supporting its potential as a biomarker and therapeutic target. Intestinal fungal dysbiosis is increasingly recognized as a component of the gut-liver axis, but its functional contribution to HCC has remained poorly defined. Our study identifies intestinal Candida albicans as a promoter of HCC progression in experimental models and delineates an IL-17A-MCP-1/PAI-1-Trem2+ macrophage circuit that links fungal exposure to impaired CD8+ T-cell immunity and reduced response to PD-1 blockade. These findings are relevant to researchers and clinicians seeking microbiome-associated determinants of HCC progression and immunotherapy resistance. Fecal C. albicans abundance and components of this immune circuit may warrant evaluation as biomarkers for patient stratification and as potential targets for combination therapy. However, the clinical associations reported here are based on modest observational cohorts, and antifungal treatment was tested as a proof-of-concept intervention in mice. Larger prospective studies and more selective therapeutic approaches will therefore be required before these findings can inform clinical management.
中文摘要:肠道白色念珠菌是否通过IL-17A和Trem2+巨噬细胞促进肝细胞癌进展及抗PD-1耐药尚不清楚。我们研究肠道白色念珠菌如何影响HCC进展、免疫重塑和ICI治疗反应。采用ITS2测序、免疫谱分析和相关性分析检测HCC、肝硬化和健康对照者的粪便和肿瘤样本。机制研究聚焦四种互补的自发性小鼠HCC模型和细胞实验,整合单细胞与批量RNA测序、遗传学和药理学干预、Kaede光转换、真菌抗原回忆试验、抗真菌治疗和抗PD-1治疗。HCC患者粪便白色念珠菌丰度较高,并与晚期疾病、较短总生存期和持久临床获益减少相关。在各HCC模型中,白色念珠菌灌胃增加肿瘤负荷,诱导以Trem2+巨噬细胞聚集及CD8+ T细胞浸润和功能受损为特征的Th17/IL-17A偏斜微环境。抗真菌治疗减轻肿瘤进展,而IL-17A阻断或缺失在很大程度上消除白色念珠菌相关促瘤作用。机制上,IL-17A通过ACT1-TRAF6-TAK1信号诱导肿瘤来源MCP-1以招募巨噬细胞,并上调PAI-1,后者激活TGF-β/Smad3信号促进免疫抑制性Trem2+巨噬细胞状态。这些巨噬细胞通过协同抑制CXCL10和诱导GAL-1限制CD8+ T细胞招募和效应功能,同时可能通过IL-1β和IL-6强化Th17反应。Kaede光转换显示肠系膜淋巴结至肝脏的Th17迁移增强,真菌抗原回忆试验显示Th17对白色念珠菌优先产生反应。白色念珠菌还损害体内抗PD-1疗效,而抗真菌治疗部分恢复治疗反应性。肠道白色念珠菌通过IL-17A-Trem2+巨噬细胞环路促进HCC进展和抗PD-1耐药,支持其作为生物标志物和治疗靶点的潜力。肠道真菌失调日益被视为肠-肝轴组成部分,但其对HCC的功能贡献仍不明确。我们的研究在实验模型中确定肠道白色念珠菌可促进HCC进展,并阐明连接真菌暴露与CD8+ T细胞免疫受损及PD-1阻断反应降低的IL-17A-MCP-1/PAI-1-Trem2+巨噬细胞环路。这些发现对寻找HCC进展和免疫治疗耐药微生物组相关决定因素的研究者和临床医生具有意义。粪便白色念珠菌丰度及该免疫环路组分可能值得作为患者分层生物标志物和联合治疗潜在靶点进行评估。然而,这些临床关联基于规模有限的观察性队列,抗真菌治疗是在小鼠中作为概念验证干预进行测试。因此,在这些发现能够指导临床管理之前,仍需更大规模的前瞻性研究和更具选择性的治疗策略。

11肝炎(病毒性/自免) (1篇)

临床研究 (1篇)

Clinical microbiology reviews IF 20.7 2026-10-26 PMID: 42929522
SUMMARYHepatitis E virus (HEV) is an important cause of viral hepatitis globally. Historically considered an acute and self-limiting illness, HEV has emerged as a significant pathogen in various immunocompromised patient groups in the last 15 years. Vulnerable patients include transplant recipients, people living with advanced HIV infection, and patients with hematological malignancies, rheumatological disorders, or autoimmune diseases. These individuals are vulnerable to chronic hepatitis and extrahepatic manifestations due to HEV. These risks are also relevant to emerging modalities of immunosuppression such as new targeted drug therapies and chimeric antigen receptor T-cell therapies. Besides unique clinical implications, immunocompromised hosts have also been at the center of new developments in the hepatitis E field on zoonotic reservoirs, transmission routes, disease models, and pathogenesis. In this review, we present a comprehensive integrative summary of the epidemiology, clinical manifestations, pathogenesis, diagnosis, and management strategies of HEV infections in immunocompromised hosts.
中文摘要:戊型肝炎病毒(HEV)是全球病毒性肝炎的重要病因。过去15年,HEV已从一种急性、自限性疾病转变为多种免疫功能低下患者群体中的重要病原体。易感人群包括移植受者、晚期HIV感染者,以及血液系统恶性肿瘤、风湿性疾病或自身免疫性疾病患者。这些人群易发生HEV相关慢性肝炎和肝外表现。新近出现的免疫抑制方式,如新型靶向药物治疗和嵌合抗原受体T细胞治疗,也带来相关风险。除独特的临床意义外,免疫功能低下宿主还处于戊型肝炎领域人畜共患储存宿主、传播途径、疾病模型和发病机制等新进展的核心。本综述对免疫功能低下宿主中HEV感染的流行病学、临床表现、发病机制、诊断和管理策略进行了综合整合总结。

12其他 (1篇)

临床研究 (1篇)

JAMA dermatology IF 10.9 2026-10-28 PMID: 42949718
Estrogen-containing therapy is considered a risk factor for porphyria cutanea tarda (PCT), but the evidence is limited to clinical series and case reports. To investigate whether estrogen-containing therapy is associated with incident PCT, overall and according to estrogen-containing therapy type and route of administration. In this matched case-control study using data from Danish nationwide registries conducted from January 1, 1995, through November 1, 2024, female individuals with a first-time hospital diagnosis of PCT were matched 1:100 with population control patients on age, sex, and index date. At least 1 redeemed prescription of estrogen-containing therapy within 1 year before the index date. Odds ratios (ORs) with 95% CIs for incident PCT were calculated from conditional logistic regression. Analyses were stratified by estrogen-containing therapy type and route of administration. Analyses were adjusted for PCT-related comorbidities: HIV infection; liver disease, viral hepatitis, or iron overload; smoking-related diagnosis or treatment; and alcohol or drug misuse diagnosis or treatment. The study included 438 female case patients with incident PCT (median age, 61.16 years [IQR, 51.08-69.17 years]) and 43 800 age-matched female control patients. In total, 154 cases (35.16%) and 9433 control patients (21.54%) had been exposed to any estrogen-containing therapy within 1 year before the index date (adjusted OR, 2.03; 95% CI, 1.66-2.49). Estrogen-containing contraceptives were associated with incident PCT (adjusted OR, 2.52; 95% CI, 1.67-3.82) as were estrogen-only therapy (adjusted OR, 1.58; 95% CI, 1.23-2.03), and combined estrogen and progestogen therapy (adjusted OR, 2.18; 95% CI, 1.53-3.11). When stratified by route of administration, oral therapy was associated with PCT (adjusted OR, 2.44; 95% CI, 1.66-3.59), whereas nonoral routes were not. This nationwide matched case-control study found that estrogen-containing therapy was associated with incident PCT. In route-specific analyses, only oral therapy was associated with PCT, suggesting that route of administration should be considered when evaluating estrogen exposure as a potential risk factor for PCT.
中文摘要:含雌激素治疗被认为是迟发性皮肤卟啉病(PCT)的危险因素,但既往证据限于临床系列和病例报告。本研究旨在探讨含雌激素治疗与初发PCT是否相关,并分析不同含雌激素治疗类型和给药途径下的关联。研究为基于丹麦全国登记资料的匹配病例对照研究,纳入1995年1月1日至2024年11月1日期间首次在医院诊断为PCT的女性,并按年龄、性别和索引日期以1:100匹配人群对照。暴露定义为索引日期前1年内至少配取1次含雌激素治疗处方。采用条件logistic回归计算初发PCT的比值比(OR)及95%CI,并按含雌激素治疗类型和给药途径分层分析。分析校正了PCT相关合并症:HIV感染;肝病、病毒性肝炎或铁过载;吸烟相关诊断或治疗;以及酒精或药物滥用诊断或治疗。研究纳入438例初发PCT女性病例(中位年龄61.16岁,IQR 51.08-69.17岁)和43800例年龄匹配的女性对照。154例病例(35.16%)和9433例对照(21.54%)在索引日期前1年内曾暴露于任何含雌激素治疗(校正OR 2.03,95%CI 1.66-2.49)。含雌激素避孕药与初发PCT相关(校正OR 2.52,95%CI 1.67-3.82),单用雌激素治疗(校正OR 1.58,95%CI 1.23-2.03)和雌激素联合孕激素治疗(校正OR 2.18,95%CI 1.53-3.11)亦相关。按给药途径分层后,口服治疗与PCT相关(校正OR 2.44,95%CI 1.66-3.59),非口服途径未见相关。这项全国性匹配病例对照研究发现,含雌激素治疗与初发PCT相关。给药途径特异性分析中仅口服治疗与PCT相关,提示评估雌激素暴露作为PCT潜在危险因素时应考虑给药途径。